Sensitivity to platinum-containing drugs is believed to be a function of how much drug enters the cell, the extent of DNA adduct formation and the rate at which DNA is repaired. Activation of protein kinase C by 12-0-tetradecanoyl-phorbol-13-acetate (TPA) DDP has activity against a relatively broad range of tumours (Loehrer & Einhorn, 1984) , and the antineoplastic activity of this drug is generally considered to result from its reaction with DNA. The majority of the adducts formed in DNA are guanine-guanine intrastrand cross-links; less than 1% of the adducts are interstrand cross-links, and a small fraction are DNA-protein cross-links (Masuda et al., 1990) .
Summary
Sensitivity to platinum-containing drugs is believed to be a function of how much drug enters the cell, the extent of DNA adduct formation and the rate at which DNA is repaired. Activation of protein kinase C by 12-0-tetradecanoyl-phorbol-13-acetate (TPA) was found to enhance the sensitivity of human ovarian carcinoma 2008 cells to cisplatin (DDP), carboplatin (CBDCA) and (glycolato-O,O') diammineplatinum(II) (254-S). TPA was able to enhance the sensitivity of the DDP-resistant 2008/C13*5.25 subline to each of the three drugs to the same extent as for the 2008 cells. TPA produced no significant change in the uptake of [3H] cis-dichloro(ethylenediamine)-platinum(II) ([3H]DEP) or CBDCA. It did not alter glutathione content or glutathione-S-transferase activity, and induced rather than suppressed metallothionein IA mRNA levels. TPA did increase the formation of intrastrand guanine-guanine cross-links by a factor of 1.5 ± 0.3 (s.d.), and reduced the fraction of intrastrand adducts removed from DNA over the subsequent 24 h by a factor of 1.3 ± 0.2 (s.d.) (n = 4; P <0.05), however, these effects were too small to account for the degree of TPA-induced sensitisation. These results indicate that the mechanism of TPA-induced sensitisation is not specific to any one structural form of platinum-containing drug, and that it is not readily explicable on the basis of an effect on the four major parameters currently believed to regulate DDP sensitivity.
DDP has activity against a relatively broad range of tumours (Loehrer & Einhorn, 1984) , and the antineoplastic activity of this drug is generally considered to result from its reaction with DNA. The majority of the adducts formed in DNA are guanine-guanine intrastrand cross-links; less than 1% of the adducts are interstrand cross-links, and a small fraction are DNA-protein cross-links ). How these cross-links cause cell death is unknown.
Four biochemical mechanisms have been identified that can influence the sensitivity of cells to DDP (reviewed in : (1) impairment of cellular uptake; (2) elevation of glutathione-S-transferase (GSH) activity (Godwin et al., 1992) ; (3) elevation of metallothioneins; and (4) variations in DNA repair. In bacteria, defects in the repair of damaged DNA are associated with hypersensitivity to DDP (Beck & Brubaker, 1973) . Likewise, defects in DNA repair processes in mammalian cells render them hypersensitive to DNA-damaging agents (Meyn et al., 1982) . Thus, DNA repair processes are important determinants of the cytotoxic effects of DNA-damaging agents in&general, and of cisplatin in particular (Plooy et al., 1985; S&renson & Eastman, 1988) . Furthermore, an increase in DNA repair capability has been reported as a mechanism of resistance to genotoxic agents in DDP-resistant murine leukaemia L1210 cells (Sheibani et al., 1989) and in DDP-resistant human ovarian cancer cells A2780cP cells (Masuda et al., 1990) .
We have previously reported that activation of protein kinase C (PKC) by TPA enhances the DPP sensitivity of the human ovarian carcinoma cell line 2008 (Ishonishi et al., 1990 , indicating that the PKC signal transduction pathway can regulate one or more of the biochemical events that determine the ability of DDP to cause cell death. This observation has been confirmed in another laboratory (Basu et al., 1990) . In this paper we report that activation of PKC can also sensitise cells to CBDCA and 254-S, two analogues whose biochemical pharmacology differs from that of DDP. We also report that the sensitising effect of TPA cannot be accounted for by effects on any of the four major parameters currently thought to regulate DDP sensitivity. (Disaia et al., 1972) . The characteristics of this line and its growth conditions have been previously described (Andrews et al., 1985) . Sensitivity to the cytotoxic effect of the platinum compounds was determined by clonogenic assay as previously described (Isonishi et al., 1990) . All experiments were done using triplicate cultures of cells in logarithmic growth, and each experiment was repeated a minimum of three times.
Materials and methods

Materials
[ (Table I ). All these differences were statistically significant (P <0.05). Thus, TPA was as effective at sensitising the resistant cells as it was at sensitising the sensitive 2008 parental cells, and therefore the mechanism must be independent of those factors that render the 2008/Cl3*5.25 cells resistant.
Modulation of sensitivity by TPA Figure 1 shows the structures of DDP, CDBCA and 254-S. All three are platinum(II) compounds, but each has a different leaving group. In the low-chloride environment of the cytosol, aquation displaces the two chlorides from DDP, the cyclobutane dicarboxylate from CBDCA and the glycolato group from 254-S. Thus all three drugs generate the same Pt(NH3)2(H20)2+ + reactive species, and produce the same types of adducts in DNA. Figure 2 shows (Isonishi et al., 1990 ).
Effect of TPA on cellular GSH content and glutathione-Stransferase activity MCB reacts quantitatively with GSH via glutathione S-transferase to form a fluorescent product readily quantitated by flow cytometry (Rice et al., 1986; Shrieve et al., 1988) . The human ovarian 2008 cells were stained with MCB for various periods of time and relative fluorescence was determined immediately by flow cytometry. Figure 4 shows a representative experiment indicating that maximum staining was obtained by 50 min, and this staining time was used for all Eastman (1983 Eastman ( , 1991 (Isonishi et al., 1990) . This drug interaction is truly synergistic when formally examined by isobologram or median effect analysis (Berebaum, 1989; Isonishi et al., 1990 (Mann et al., 1990 ) and a small increase in GSH (Andrews et al., 1988) (Friedberg, 1985) , including HI histone (Sahoun et al., 1983) , RNA polymerase II (Chuang et al., 1987) , topoisomerase (Sahyoun et al., 1986; Samuels et al., 1989) , and DNA polymerase (Krauss et al., 1987) . Finally, it is important to note that, in addition to PKC, n-and P-chimaerin have now been identified as targets for the binding of TPA (Ahmed et al., 1993; Leung et al., 1993) , and it is possible that the effects on platinum-containing drug sensitivity are mediated by activation of signal transduction pathways other than those in which PKC is involved. While the results reported here establish that TPA enhances the sensitivity of human ovarian cells to three different platinum(II)-containing drugs in both sensitive and resistant cells, the mechanism of this effect remains to be defined, and it-is important to emphasise that PKC may be producing other changes in cellular metabolism, unrelated to the biochemical pharmacology of these drugs, that also influence sensitivity. This work was supported by Grant CA-35309 from the National Institutes of Health, Grants CH-377, 486 and 368 from the American Cancer Society, a grant from Bristol-Myers Squibb and a grant from the Jikei University School of Medicine, Tokyo, Japan. This work was conducted in part by the Clayton Foundation for Research, California Division. Dr Howell is a Clayton Foundation Investigator.
